Maha Katabi, Director at Vera Therapeutics, Inc. (VERA), bought 161,290 shares at $31.00 ($5.0M) on 2024-01-30, disclosed to the SEC on 2024-02-01.
Open-market purchase of $5.0M VERA by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| Filing → |
| VERA | BUY | 2022-02-14 | $4.0M | — | Filing → |
| AVTE | BUY | 2021-07-06 | $5.0M | — | Filing → |
| VERA | BUY | 2021-05-18 | $8.0M | — | Filing → |